Yield10 Bioscience, Inc. Common Stock
YTEN
YTEN was delisted on the 15th of May, 2024.
10 hedge funds and large institutions have $7.62M invested in Yield10 Bioscience, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
16% more capital invested
Capital invested by funds: $6.59M → $7.62M (+$1.03M)
11% more funds holding
Funds holding: 9 → 10 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $5K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$29.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14.8K |
| 3 |
FA
FCG Advisors
Chatham,
New Jersey
|
+$14.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$311K |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
-$183K |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
-$1K |
YTEN Hedge Fund Activity: Q1 2016 in Review
10 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Yield10 Bioscience, Inc. Common Stock (YTEN) for Q1 2016, worth a combined $7.62M — up 16% from $6.59M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new YTEN positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $29.6K. The largest seller was Oracle Investment Management, cutting an estimated $311K.
- 10 institutional investors held Yield10 Bioscience, Inc. Common Stock (YTEN) as of Q1 2016, up from 9 in Q4 2015.
- Funds reported $7.62M of Yield10 Bioscience, Inc. Common Stock stock for Q1 2016, up 16% quarter-over-quarter.
- 2 funds opened new Yield10 Bioscience, Inc. Common Stock positions in Q1 2016 and 1 closed out, a net change of +1 holder.
- The largest Yield10 Bioscience, Inc. Common Stock buyer in Q1 2016 was UBS Group, an estimated $29.6K added.
- The largest Yield10 Bioscience, Inc. Common Stock seller in Q1 2016 was Oracle Investment Management, an estimated $311K sold.
Based on aggregated 13F filings for Q1 2016.